Immunoglobulin G1, Anti-(Human Mesothelin) (Human Monoclonal Mf-T-Igg1 Heavy Chain), Disulfide With Human Monoclonal Mf-T-Igg1 .Lambda.-Chain, Dimer, N6-(4-((4-(3-(Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)-2-((Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)Methyl)Propyl)Phenyl)Amino)-1,4-Dioxobutyl)-L-Lysine Complex With Thorium-227Th
Pancreatic Ductal Adenocarcinoma
Explore 280 assets in Pancreatic Ductal Adenocarcinoma →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Bayer
Modality
antibody_drug_conjugate
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03507452CT.gov First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Ductal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human Mesothelin) (Human Monoclonal Mf-T-Igg1 Heavy Chain), Disulfide With Human Monoclonal Mf-T-Igg1 .Lambda.-Chain, Dimer, N6-(4-((4-(3-(Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)-2-((Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)Methyl)Propyl)Phenyl)Amino)-1,4-Dioxobutyl)-L-Lysine Complex With Thorium-227Th (this asset) | Bayer | P1 | CC · 47 |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | OHSU Knight Cancer Institute | P2 | BB |
| Rmc-6236 | Tango Therapeutics, Inc. | P3 | BB |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| S-1 | Genentech, Inc. | P2 | BB |
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone | Corcept Therapeutics | P3 | BB |
| Metformin | British Columbia Cancer Agency | P2 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Ivospemin | Panbela Therapeutics, Inc. | P2/3 | BB |
+42 more in the Pancreatic Ductal Adenocarcinoma cohort
Other indications for Immunoglobulin G1, Anti-(Human Mesothelin) (Human Monoclonal Mf-T-Igg1 Heavy Chain), Disulfide With Human Monoclonal Mf-T-Igg1 .Lambda.-Chain, Dimer, N6-(4-((4-(3-(Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)-2-((Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)Methyl)Propyl)Phenyl)Amino)-1,4-Dioxobutyl)-L-Lysine Complex With Thorium-227Th
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pleural Epithelioid Mesothelioma | — | P1 | CC · 47 |
| Malignant Peritoneal Mesothelioma | — | P1 | CC · 47 |
| Ovarian Serous Adenocarcinoma | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerOHSU Knight Cancer InstituteBB
- Rmc-6236Tango Therapeutics, Inc.BB
- DaraxonrasibRevolution Medicines, Inc.BB
- S-1Genentech, Inc.BB
- (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)MethanoneCorcept TherapeuticsBB
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human Mesothelin) (Human Monoclonal Mf-T-Igg1 Heavy Chain), Disulfide With Human Monoclonal Mf-T-Igg1 .Lambda.-Chain, Dimer, N6-(4-((4-(3-(Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)-2-((Bis(2-(((1,2-Dihydro-3-(Hydroxy-.Kappa.O)-1-Methyl-2-(Oxo-.Kappa.O)-4-Pyridinyl)Carbonyl)Amino)Ethyl)Amino)Methyl)Propyl)Phenyl)Amino)-1,4-Dioxobutyl)-L-Lysine Complex With Thorium-227Th in Pancreatic Ductal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-mesothelin-human-monoclonal-mf-t-igg1-heavy-chain-disulfide-with-human-monoclonal-mf-t-igg1-lambda-chain-dimer-n6-4-4-3-bis2-12-dihydro-3-hydroxy-kappao-1-methyl-2-oxo-kappao-4-pyridinylcarbonylaminoethylamino-2-bis2-12-dihydro-3-hydroxy-kappao-1-methyl-2-oxo-kappao-4-pyridinylcarbonylaminoethylaminomethylpropylphenylamino-14-dioxobutyl-l-lysine-complex-with-thorium-227th-pancreatic-ductal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →